Helix BioPharma Corp., a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, has announced a significant restructuring of its Board of Directors. Effective September 28, 2026, Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt have been appointed to the Board. Ms. Krumeich will also serve as Chair of the Board and Audit Committee. Concurrently, Jacek Antas, Malgorzata Laube, and Jerzy Leszczynski have voluntarily resigned. This planned renewal, initially reported by NEWMEDIAWIRE, underscores Helix's commitment to strengthening its governance and strategic direction.
The new board members bring a diverse and complementary set of skills that directly address the challenges and opportunities facing a clinical-stage oncology company. Karen Krumeich, a seasoned life sciences financial executive, has served as CFO for multiple public and private companies with oncology programs, including Kazia Therapeutics and Soligenix. Her expertise in venture and public equity financing, investor relations, and corporate governance will be critical as Helix seeks to fund its pipeline. Jamieson Bondarenko, a Chartered Financial Analyst and Chartered Market Technician, brings capital markets experience from roles at Eight Capital and Dundee Securities, and currently chairs the board of BriaCell Therapeutics. Charmaine Lykins, a commercial leader with over 30 years in biopharmaceuticals, has held senior roles at Karuna Therapeutics, Acadia Pharmaceuticals, and Eli Lilly, contributing to the launch of numerous blockbuster therapies. Dirk Brockstedt, a scientist with more than 25 years in research and clinical development, served as Chief Scientific Officer of RAPT Therapeutics until its acquisition by GSK in 2026, and has deep expertise in immunology and oncology.
This board overhaul matters because it strategically positions Helix to advance its pipeline, which includes L-DOS47, a clinical-stage antibody-enzyme conjugate for non-small cell lung cancer, and two pre-IND candidates, LEUMUNA and GEMCEDA. The addition of Krumeich, with her audit and finance background, and Bondarenko, with his capital markets acumen, signals a focus on financial discipline and access to capital. Lykins's commercialization experience is vital for eventual market entry, while Brockstedt's scientific and clinical development expertise can guide the company through regulatory hurdles. As CEO Thomas Mehrling noted, the new members bring "an exceptional breadth of complementary expertise" that will be "invaluable as we advance our oncology pipeline, execute our strategic objectives, and position Helix for sustainable, long-term value creation for our shareholders."
Following these changes, the Board comprises six directors, four of whom are independent, and the Audit Committee is now entirely independent. This governance structure aligns with best practices and may enhance investor confidence. For a company like Helix, which operates in the high-risk, high-reward field of oncology drug development, a strong board can provide critical oversight and strategic guidance. The resignations of Antas, Laube, and Leszczynski, while voluntary, reflect a deliberate renewal process rather than a reaction to any disclosed issues. The company's forward-looking statements emphasize the risks inherent in R&D, but the new board's collective experience could mitigate some of these challenges.
Investors and stakeholders can find more details about Helix BioPharma and its pipeline at https://www.helixbiopharma.com/, and regulatory filings are available on SEDAR+ at www.sedarplus.ca. The changes come at a pivotal time as Helix seeks to differentiate itself in the competitive oncology space. With a reinforced board, the company is better equipped to navigate the complexities of clinical development, financing, and eventual commercialization. The market will be watching closely to see if this governance upgrade translates into tangible progress for patients and shareholders alike.
